Russ Conroy

Hillsborough

Assistant Editor at Cancer Network

Featured in: Favicon

cancernetwork.com Favicon

newsbreak.com Favicon

ajmc.com

onclive.com Favicon

curetoday.com Favicon

targetedonc.com Favicon

urologytimes.com Favicon

oncnursingnews.com Favicon

dermatologytimes.com Favicon

drugtopics.com

Articles

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

1 day ago | cancernetwork.com | Russ Conroy

The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) as a treatment for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) and high c-MET protein expression previously managed wih systemic therapy, according to a press release from the developer, AbbVie.1With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.
Phase 2B Glioblastoma Vaccine Trial Cleared to Continue

1 day ago | oncnursingnews.com | Russ Conroy

The phase 2b SURVIVE trial (NCT05163080) evaluating SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will continue without modification following an interim analysis, according to a press release from Roswell Park Comprehensive Cancer Center.1Findings from the recently completed interim futility analysis and ongoing assessment by an independent data safety monitoring board indicated that the SURVIVE trial could continue as planned without any protocol changes.
Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

3 days ago | cancernetwork.com | Russ Conroy

Based on an interim analysis of trial data, the phase 2b SURVIVE study (NCT05163080) assessing SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will continue, according to a press release from Roswell Park Comprehensive Cancer Center.1Findings from the recently completed interim futility analysis and ongoing assessment by an independent data safety monitoring board indicated that the SURVIVE trial could continue as planned without any protocol changes.
Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities

5 days ago | cancernetwork.com | Russ Conroy

Better support for breastfeeding may help avoid new cases of triple-negative breast cancer (TNBC) in patients who are White or Black, according to findings from a pooled analysis study published in NPJ Breast Cancer.1Breastfeeding for less than 6 months conferred higher odds of TNBC for those who were White (pooled odds ratio [pOR], 1.41; 95% CI, 1.15-1.74; I2 = 67%) or Black (pOR, 1.35; 95% CI, 1.06-1.73; I2 = 0%).
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

6 days ago | cancernetwork.com | Russ Conroy

Treatment with revumenib produced clinically meaningful responses in an older population of patients with heavily pretreated relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations, according to findings from the phase 2 portion of the phase 1/2 AUGMENT-101 study (NCT04065399) published in Blood.1Among 64 evaluable adult patients, a complete response (CR) or CR with partial hematologic recovery (CRh) occurred in 23.4% (95% CI, 13.8%-35.7%; 1-sided P = .0014).
Chemoradiation Shows Responses Across Dose Levels in Anal Cancer

6 days ago | cancernetwork.com | Russ Conroy

Intensity-modulated radiotherapy (IMRT) demonstrated favorable 6-month complete clinical responses administered at a standard or reduced dose among patients with early-stage anal cancer, according to findings from the phase 2 PLATO-ACT4 trial (ISRCTN88455282) published in Lancet Oncology.1 At 6 months, a complete clinical response occurred in 84.4% (n = 135/160) of all evaluable patients, with respective rates of 84% (n = 46/55; 95% CI, 71.2%-92.2%) and 85% (n = 89/105; 95% CI, 76.4%-91.0%)...
Frontline Efti Combo Yields Meaningful Survival in PD-L1-Low HNSCC

1 week ago | cancernetwork.com | Russ Conroy

Combining eftilagimod alfa (efti) with pembrolizumab (Keytruda) demonstrated an overall survival (OS) benefit in the first-line treatment of a small cohort of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) harboring a PD-L1 combined positive score (CPS) of less than 1, according to a press release on cohort B findings from the phase 2b TACTI-003/KEYNOTE-C34 trial (NCT04811027) .1 With a data cutoff date of March 31, 2025, the median OS among 31 evaluable...
Racial, Ethnic Disparities Present in Pediatric Brain Cancer Survival

1 week ago | oncnursingnews.com | Russ Conroy

Black and Hispanic pediatric patients with high-risk neuroblastoma experienced lower overall survival (OS) rates, per data from a retrospective cohort study published in JAMA Network Open.1Among patients who were included in induction/consolidation trials, the 5-year OS rate was 47.2% and 61.3% for patients who were Hispanic and White, respectively (HR, 1.55; 95% CI, 1.11-2.15; P = .047).
Cemsidomide Combo May Produce Responses in Multiple Myeloma

1 week ago | cancernetwork.com | Russ Conroy

Treatment with cemsidomide (CFT7455) plus dexamethasone elicited responses across multiple doses in a small cohort of patients with multiple myeloma, according to a press release on findings from the phase 1/2 CFT7455-1101 study (NCT04756726) from the drug’s developer, C4 Therapeutics, Inc.1With a data cutoff date of April 30, 2025, cemsidomide at a dose of 100 µg once daily produced an overall response rate of 50% among 10 evaluable patients.
FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

1 week ago | cancernetwork.com | Russ Conroy

The FDA has lifted its clinical hold on the investigational new drug applications for tabelecleucel (tab-cel; Ebvallo) as a treatment for those with Epstein-Barr Virus (EBV)–positive post-transplant lymphoproliferative disease (PTLD), according to a news release from the developer, Atara Biotherapeutics, Inc.1 The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection...